Abstract: The present disclosure relates, in general, to: (a) solid pharmaceutical dosage forms comprising acalabrutinib maleate; (b) methods of using such pharmaceutical dosage forms to treat B-cell malignancies and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods.

Abstract: A solar powered sign annunciator comprised of a plurality of high intensity light emitting diodes (LED); a microprocessor controller to regulate power consumption and annunciator characteristics, battery charging and sensor response with an integrated software charge controller; a minimalized solar panel array sized to produce sufficient power for battery charging under normalized solar radiation to latitudes as far north as 45 degrees; a direction sensing Doppler radar to determine the approach of traffic; a low voltage battery to minimize power control losses to the LED array; a temperature sensor to determine proper charging battery status and battery capacity; and a plurality of analog to digital (A/D) converters incorporated in the microprocessor to sense solar power output, temperature input, battery voltage and charging current and Doppler phase shift differential.